A Danish biotechnology company focused on the discovery and development of antibody-based therapies, particularly for cancer and other serious diseases. Its business model combines in-house drug development with partnerships that generate milestone payments and royalty streams, most notably from the...
No congressional trades have been disclosed for Genmab A/S (GMABY) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.